Congratulations Dr. Andrea Verdugo-Meza and Helen Chiang for their publication of the perspective article, “Not quite a cure yet: unlocking the unfulfilled promise of live biotherapeutics for disease treatment”. In this paper, we highlighted the shortcomings of probiotics and live biotherapeutic products (LBPs) when intestinal inflammation is involved. While probiotics and LBPs have the potential for health benefits, the inflamed intestine is a harsh environment for these beneficial microbes to thrive, therefore they must be tailored to tolerate such condition to exert their benefits. Our EcN:ttr (BioPersistTM) was bio-engineered in our lab to thrive in the inflamed gut and dampen the inflammation.
Read the full article here!









Dr. Gibson was awarded the prestigious Killam Faculty Research Fellowship to support her sabbatical project in India “Characterization of differences in the gut microbiome composition and function between cohorts of South East Asians, immigrants and 1st generation Indo-Canadians.”